{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:11:28Z","timestamp":1791947488065,"version":"4.3.4"},"reference-count":29,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2008,3,26]],"date-time":"2008-03-26T00:00:00Z","timestamp":1206489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Estimation of the population\u2010based relative incidence (RI) of contact sensitization to a set of topical drug allergens (cases\/100\u2009000 defined daily doses (DDDs) per year) (1995\u20132004) and comparison of the RI for drugs with a similar therapeutic scope.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clinical data regarding the frequency of contact sensitization to important topical drug allergens in Germany were obtained from the Information Network of Departments of Dermatology (IVDK). This was extrapolated to the general population level using the \u2018clinical epidemiology and drug utilization research\u2019 (CE\u2010DUR) approach. As denominator of exposure, national prescription data (DDDs of topical drug specialties) provided by the WIdO Research Institute (Bonn) were aggregated per substance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The probable RIs of contact sensitization to topical \u2018skin\u2019 corticosteroids ranged from 0.3 (dexamethasone phosphate disodium salt) to 23.3 (amcinonide) cases\/100\u2009000 DDDs per year. Concerning topical aminoglycoside antibiotics, the RI of framycetin sulphate was about threefold higher than that of gentamicin sulphate. Regarding topical ophthalmic use, the RI of kanamycin sulphate was higher compared to gentamicin sulphate. Active principles marketed over\u2010the\u2010counter (OTC) had, in general, lower RIs, with the exception of bufexamac, benzocaine, clioquinol and phenylephrine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The population\u2010based risk assessment\u2014quantitatively considering exposure in the RI estimation\u2014revealed a ranking of contact sensitization risk to topical drugs which partly differed from the respective frequencies in the clinical patch test population. Some drugs available OTC carry non\u2010negligible risk, too. The current findings should contribute to differential therapeutic considerations regarding topical drug use. Copyright \u00a9 2008 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1588","type":"journal-article","created":{"date-parts":[[2008,3,26]],"date-time":"2008-03-26T13:55:19Z","timestamp":1206539719000},"page":"813-821","source":"Crossref","is-referenced-by-count":38,"title":["Allergic contact dermatitis to topical drugs\u2014epidemiological risk assessment"],"prefix":"10.1002","volume":"17","author":[{"given":"C. A. Menezes","family":"de P\u00e1dua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schnuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Nink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pfahlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Uter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,3,26]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-31301-X_35"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100536.1998. tb05928.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100536.1999.tb06116.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100536.1999.tb06254.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/archderm.1979.04010080023015","article-title":"Allergic contact hypersensitivity to nickel, neomycin, ethylendiamin, and benzocaine\u2014relationships between age, sex, history of exposure, and reactivity to standard patch tests and use tests in a general population","volume":"115","author":"Prystowsky SD","year":"1979","journal-title":"Arch Dermatol"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.2340\/0001555572456460","article-title":"Allergic contact sensitization in an unselected Danish population. The Glostrup Allergy Study, Denmark","volume":"72","author":"Nielsen NH","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398\u20109995.2001.00086.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j. jclinep. 2003.04.002"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100536.2007.00980.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2007.01218.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1268"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600\u20100536.2002.470107.x"},{"key":"e_1_2_1_14_2","first-page":"36","article-title":"The epidemiology of contact dermatitis. The information network of departments of dermatology (IVDK) in Germany","volume":"8","author":"Uter W","year":"1998","journal-title":"Eur J Dermatol"},{"key":"e_1_2_1_15_2","volume-title":"Anatomisch\u2010 therapeutisch\u2010 chemische Klassifikation mit Tagesdosen f\u00fcr den deutschen Arzneimittelmarkt. Methodik der ATC\u2010Klassifikation und DDD\u2010Festlegung. ATC\u2010Index mit DDD\u2010Angaben (on CD\u2010ROM)","author":"Fricke U","year":"2005"},{"key":"e_1_2_1_16_2","unstructured":"Statistisches Taschenbuch Gesundheit.2005.http:\/\/www.bmg. bund.de\/nn_601090\/DE\/Statistiken\/Statistiken\u2010Gesundheit\/Statistische\u2010Taschenbuecher\/Ausgabe_202005\/ausgabe\u20102005\u2010node param=.html__nnn=true[3 November 2006]."},{"key":"e_1_2_1_17_2","volume-title":"Arzneiverordnungsreport (2005)","author":"Schwabe U","year":"2005"},{"key":"e_1_2_1_18_2","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology.The ATC\/DDD system.http:\/\/www.whocc.no\/atcddd\/[1 May 2007]."},{"key":"e_1_2_1_19_2","unstructured":"Rote Liste 2004. (on CD\u2010ROM). ed. Aulendorf: ECV 2004."},{"key":"e_1_2_1_20_2","first-page":"91","volume-title":"Statistik Lehr\u2010 und Handbuch der angewandten Statistik","author":"Hartung J","year":"1999"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105\u20101873. 2004.00406.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000156354.20227.F0"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315097"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000170"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20102005\u2010923320"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105\u20101873.2004.00334.x"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102133.1989.tb01396.x"},{"key":"e_1_2_1_28_2","first-page":"43","article-title":"Reactions to corticosteroids: some new aspects regarding cross\u2010sensitivity","volume":"65","author":"Goossens A","year":"2000","journal-title":"Cutis"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600\u20100536.2000.043001041.x"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600\u20100536.2001.440511\u20106.x"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1588","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T20:53:38Z","timestamp":1695934418000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,26]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1002\/pds.1588"],"URL":"https:\/\/doi.org\/10.1002\/pds.1588","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,26]]}}}